Biomarin Pharmaceutical (BMRN) Change in Inventory (2009 - 2026)

Biomarin Pharmaceutical has disclosed Change in Inventory across 18 years of filings, most recently posting -$44.5 million for Q1 2026.

• Quarterly Change in Inventory fell 282.82% year-over-year to -$44.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.1 million (down 32.29% YoY) and the FY2025 annual result came in at $116.9 million, up 84.05% from the prior year.
• Change in Inventory retreated to -$44.5 million in Q1 2026, from $18.1 million in the prior quarter.
• Over five years, Change in Inventory peaked at $59.1 million in Q4 2023 and troughed at -$44.5 million in Q1 2026.
• A 5-year average of $21.3 million and a median of $26.0 million in 2022 frame the typical range for Change in Inventory.
• Annual changes were most pronounced in 2023 — Change in Inventory soared 1557.98% — and 2026, when it sank 282.82%.
• Tracing BMRN's Change in Inventory over 5 years: stood at $40.8 million in 2022, then soared by 44.72% to $59.1 million in 2023, then plunged by 42.02% to $34.3 million in 2024, then tumbled by 47.09% to $18.1 million in 2025, then slumped by 345.35% to -$44.5 million in 2026.
• Business Quant data shows BMRN's Change in Inventory at -$44.5 million in Q1 2026, $18.1 million in Q4 2025, and $26.3 million in Q3 2025.